Navidea Biopharmaceuticals’s Lymphoseek® Recommended By CHMP For European Approval In Sentinel Lymph Node Detection For Melanoma, Breast And Certain Head And Neck Cancers

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) has announced that that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing authorization for Lymphoseek® 250 micrograms kit for radiopharmaceutical preparation (tilmanocept) in the European Union (EU). The recommendation is for Lymphoseek use in imaging and intraoperative detection of sentinel lymph nodes draining a primary tumor in adult patients with breast cancer, melanoma, or head and neck oral cavity squamous cell carcinoma.

Help employers find you! Check out all the jobs and post your resume.